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Abstract: Poor adherence to statin therapy is linked to significantly increased risk of cardio-
vascular events and death. Unfortunately, adherence to statins is far from optimal. This is an 
alarming concern for patients prescribed potentially life-saving cholesterol-lowering medication, 
especially for those at high risk of cardiovascular events. Research on statin adherence has only 
recently garnered broader attention; hence, major reasons unique to adherence to statin therapy 
need to be identified as well as suggestions for countermeasures. An integrated approach to 
minimizing barriers and enhancing facilitation at the levels of the patient, provider, and health 
system can help address adherence issues. Health care professionals including physicians, 
pharmacists, and nurses have an obligation to improve patient adherence, as routine care. In 
order to achieve sustained results, a multifaceted approach is indispensable.
Keywords: cardiovascular disease, nonadherence, nocebo, myopathy, statins
Nonadherence to statin therapy: a growing concern 
in prevention of cardiovascular disease
Cardiovascular disease (CVD) is the number one cause of death globally. About 17.7 
million people died from CVD in 2015, representing 31% of global mortality.1 Of 
these deaths, coronary heart disease (CHD) and stroke contributed to 7.4 and 6.7 
million deaths, respectively.1
High cholesterol, especially elevated low-density lipoprotein cholesterol (LDL-C) 
levels, increases the risk of heart disease and stroke.2–5 Globally, a third of ischemic heart 
disease is attributable to high cholesterol and responsible for 2.6 million deaths a year.6
More than three-quarters of deaths due to CVD occur in low- and middle-income 
countries.1 It is predicted that CVD will be responsible for even more deaths in the 
developing world than the current common causes of diseases added together and will 
continue to dominate mortality trends in the foreseeable future.7–9 Increased incidence 
and prevalence of CVD has seen an upsurge of health care expenditures in many coun-
tries due to rising number of patients and costs of preventive measures and treatment.8
The improved awareness and management of cardiovascular risk factors has resulted 
in a 50% decrease in deaths from CHD over the past 30 years.10 Medical advances 
in the past decade, particularly the introduction of potent statins such as atorvastatin 
and rosuvastatin, have made achieving lower LDL-C levels within reach for most 
individuals at risk of CVD.11 However, more and more patients are not at LDL-C 
target; nonadherence to medicines is said to be responsible for the failure to achieve, 
but more importantly, to retain LDL-C targets.11 This prioritizes the need to identify 
problems with adherence in a clinical context.
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Adherence to prescribed medicines predicts outcomes, 
and better outcomes significantly lower associated health 
care costs.12–14 In a cohort study of 59,000 new statin users 
in the Netherlands, compliance with statin therapy for at 
least 2 years was associated with a 30% reduction in risk 
of hospitalization for acute myocardial infarction with an 
increase in protective effect with higher doses.
Likewise, a systematic review of 19 studies reported a 
relative risk of statin discontinuation ranging from 1.22 to 
5.26 for CVD and 1.25 to 2.54 for death.15 Another retrospec-
tive cohort study conducted in >229,000 patients reported a 
direct association between survival and adherence to statin 
therapy.13 Current estimates suggest that statin nonadherence 
generates US $44 billion extra, but avoidable, health care 
costs in the USA.16
Despite the evidence of improved outcomes, adherence 
to guideline-recommended statin therapy is suboptimal, and 
almost 80% of high-risk patients do not reach guideline-
recommend LDL-C targets.8,17,18 Two key issues appear to 
be at play. First is the lack of high-intensity statin prescrip-
tions in the appropriate dosage by physicians starting treat-
ment,19 resulting in a significant proportion of un(der)treated 
high-risk patients.18 Second is the under-use of statins by 
patients.20 A recent real-world evidence study assessing the 
effectiveness of lipid-lowering therapy on LDL-C in high 
CVD risk patients in a primary care setting in Italy found 
only 61% adherent to therapy 3 months after the initial 
statin prescription, and barely 55% were adherent after 6 
months.21 Approximately 50% of patients with CVD and/
or its major risk factors demonstrate poor adherence to their 
prescribed medicines.22 Even in the immediate period fol-
lowing acute coronary events, adherence is not optimal.23 
In a cohort study using linked population-based data from 
Ontario, 60% of patients with post-acute coronary syndrome 
(N=22,379) discontinued their statin therapy within 2 years 
of hospitalization.24
For a treatment with such well-documented CVD mor-
bidity and mortality benefits, these rates are strikingly low.25 
Novel methods to help patients improve their adherence to 
existing evidence-based cardiovascular drug therapies have 
a powerful potential to improve patient outcomes and reduce 
associated health care expenditure.23
Role of statins in the prevention of 
CVD
Standard of care
Since their introduction in 1987, statins have been considered 
one of the key interventions associated with the decline of 
cardiovascular morbidity and mortality.25 By lowering LDL-
C, statins have significantly decreased cardiovascular events 
in both primary and secondary CVD prevention  trials.14 
Statins also help stabilize arterial plaques present in the blood 
vessels of the brain and heart, reducing the risk of stroke and 
CHD-related events.26
The use of statins has increased as a result of expand-
ing indications, guidelines emphasizing intensification of 
LDL-C lowering goals, rising number of generics, as well 
as recommendations on earlier screening and treatment.14 
Clearly, statins have now become the universally accepted 
standard of atherosclerotic cardiovascular disease care, to 
the extent that clinical trials of new lipid-lowering drugs are 
being conducted as add-ons to statins rather than as novel 
stand-alone therapies.14,27
The benefits of statin therapy observed in randomized 
clinical trials can only be realized if patients adhere to the 
prescribed treatment regimens.14 For those who discontinue 
statin treatment, the number needed to harm (NNH) based 
on mortality is 1 excess death for every 83 patients.25 The 
NNH with reference to CVD is 59 per year.25
Medicine-related adverse events
Statins are generally very well tolerated with three major 
documented side effects linked to their use. Serious adverse 
events (AEs) associated with statin therapy include myopa-
thy, new-onset diabetes mellitus (NODM), and hemorrhagic 
stroke.28 Five cases of myopathy may be seen when 10,000 
patients are treated for 5 years with statins as recommended 
by guidelines; 50–100 new cases of diabetes or 5–10 cases 
of hemorrhagic strokes may result as well.28
Statin-associated muscle symptoms
Statin-associated muscle symptoms (SAMS) can be myalgia, 
myopathy, or rhabdomyolysis (Table 1). Rhabdomyolysis 
is the most severe manifestation and can lead to further 
complications such as renal failure.28,29 In very rare cases, 
an autoimmune myopathy develops in patients treated with 
statins; this autoimmune disorder is characterized by muscle 
symptoms, evidence of muscle-cell necrosis on biopsy, 
and the presence of autoantibodies against 3-hydroxy-
3-methylglutaryl coenzyme A (HMG-CoA) reductase. This 
is estimated to occur in ~2 or 3 of every 100,000 patients 
treated with statins.30 In most cases, patients exhibit only 
mild-to-moderate muscle weakness. Some patients may have 
progressive weakness that may require immunosuppressive 
therapy (Table 1).30 If creatinine kinase levels persist ≥10 
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tinuation of the statin or if symptoms progress after statin 
discontinuation, autoantibodies for HMG-CoA reductase 
should be tested.31
The development of SAMS does not always suggest 
intolerance to statins. Not all reported muscle complaints are 
caused by statins per se. With aging, muscular-skeletal pathol-
ogy can manifest and be misinterpreted as statin related.32 
Some patients are able to tolerate SAMS at a lower dose, 
with a longer dosing interval, or with an alternative statin.33 
Rechallenged patients who discontinued statin therapy as a 
result of reported statin-associated effects were able to toler-
ate statins for a long term.34 It is therefore vital for health 
providers to determine if an individual is truly intolerant to 
statins or not.
New-onset diabetes mellitus
There is a reported 10%–12% increase in NODM among 
patients receiving statins; this risk increases with more 
intensive treatment and in patients with prediabetes.35 Earlier 
and more persistent use of high-dose, high-intensity statins 
appears to correlate with a greater increase in the risk of 
NODM. This, however, is offset by the proportionally larger 
reduction in cardiovascular events and death.36
Statins are prescribed on the basis of CVD risk and indi-
vidual patient characteristics; diet and lifestyle interventions 
should be emphasized to help mitigate the risk of NODM.35 
For instance, weight control has been recommended to pre-
vent statin-related NODM.36
Hemorrhagic stroke
In observational studies, blood cholesterol concentrations 
have been negatively associated with rates of hemorrhagic 
stroke.28 Conversely, in a meta-analyses of large statin trials, 
no increased risk of intracerebral hemorrhage (ICH) was 
found, most likely as a consequence of a low absolute risk of 
ICH.37 Based on the SPARCL trial, an increased risk of ICH 
may only be associated with elderly patients who have a his-
tory of ICH and poorly controlled hypertension particularly 
while using high-dose statins.38
Acute memory loss has also been reported with the use of 
statins. However, these findings have been inconsistent, and 
studies of long-term statin use have found either improved 
memory or no effect.28,39
Statin intolerance
Statin intolerance can be defined as the occurrence of muscle 
symptoms or other AEs that lead to the discontinuation of statin 
therapy.40 Although muscle-related AEs may occur with statins, 
“true” statin intolerance is uncommon.41 Statin intolerance may 
prevent a large proportion of patients from continuing statin 
therapy for a long term. Placebo-controlled randomized tri-
als show that most AEs that are attributed to statin therapy in 
routine practice are not actually caused by it.28 These claims 
of AEs are based on nonrandomized observational studies and 
are not supported by the evidence from randomized-controlled 
trials.29 It is vital, but challenging, to differentiate between 
individuals who are truly intolerant to statins and those who can 
actually tolerate them.40 This is because management of “true” 
statin intolerance requires a totally different approach. “True” 
statin intolerance is suggested if a patient has unacceptable 
muscle-related symptoms that resolve with discontinuation 
of therapy and occur with rechallenge on at least two to three 
statins and one of which is prescribed at the lowest approved 
dose.41 Most guidelines recommend restarting at a lower dose 
and/or a different statin (maximally tolerated statin dose) after 
symptoms subside combined with non-statin lipid-lowering 
therapies to attain recommended LDL targets.42–44 In 2017, 
the Expert Consensus Decision Pathway writing committee of 
the American College of Cardiology (ACC) provided updated 
recommendations on the use of non-statins. Addition of a 
non-statin cholesterol-lowering therapy (either ezetimibe or 
a proprotein convertase subtilisin/kexin 9 [PCSK9] inhibitor) 
is recommended for high-risk patients who are statin intoler-
ant. Bile acid sequestrants are recommended only in patients 
intolerant to ezetimibe.41
The lipid-lowering capability of the two recommended 
non-statin medications, ezetimibe and evolocumab (a 
PCSK9 inhibitor), was compared in the GAUSS-3 (Goal 
Table 1 Classification of SAMS
Category Definition
Myalgia Muscle pain or weakness only
Myopathy Muscle symptoms with a raised CK <10×ULN
Rhabdomyolysis Muscle symptoms with a raised CK >10×ULN
Autoimmune myopathy Muscle symptoms with muscle cell necrosis and presence of HMG-CoA reductase autoantibodies. CK levels persist 
≥10 times the ULN 8 weeks after discontinuation of the statin.
Notes: Data compiled from Collins et al, Sathasivam and Lecky, Mammen, and Sweidan et al.28–31
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 Achievement After Utilizing an Anti-PCSK9 Antibody in 
Statin Intolerant Subjects 3) trial in patients with documented 
clinical statin intolerance.45 Evolocumab resulted in signifi-
cantly greater reduction in LDL-C after 24 weeks compared 
with ezetimibe. Subcutaneously administered PCSK9 inhibi-
tors have demonstrated marked reduction in LDL-C both 
as a monotherapy and when combined with statin and/or 
ezetimibe therapy.46 National Lipid Association 2017 Expert 
Panel on treatment with PCSK9 inhibitors recommend these 
agents in selected very-high-risk statin-intolerant patients.46 A 
recent meta-analysis has also concluded their efficacy, safety, 
and tolerability in statin-intolerant patients.47
However, there are several arguments against treating 
statin-intolerant patients with PCSK9 inhibitors.48 First, 
PCSK9 inhibitors are not approved for this indication.48 Sec-
ond, these agents do not have successful long-term outcomes 
like statins yet. Third, some statin-intolerant patients still may 
report muscle-related adverse effects as seen in GAUSS-3 
trial, and lastly, they are very expensive, and pharmacoeco-
nomic analysis is required to identify patient sub-groups 
where “value for money” can be clearly demonstrated.45
Hence, it is vital for physicians to ensure that their patients 
are aware of the possible statin-associated side effects when 
prescribing the medicine. This should be done without rais-
ing any unnecessary negative expectations and at the same 
time encouraging patients’ understanding of benefits of statin 
treatment to promote adherence to therapy.33
Interracial variation and statin intolerance
It has been reported that Asians respond differently to 
statins than Western populations.49 Several studies have 
demonstrated an increased systemic exposure with rosuv-
astatin in Asians.50–52 Data indicate that polymorphisms in 
the SLCO1B1 and ABCG2 genes contribute to this differ-
ence.49,53,54 However, this phenomenon is not a class effect 
among other high-intensity statins and should not be seen 
as a barrier to prescription of higher doses of other statins. 
No difference has been identified in systemic exposure with 
atorvastatin between Asians and Caucasians.55 Atorvastatin 
(10–80 mg) has been found to be equally efficacious and safe 
in Asian and Western populations.56,57 Therefore, there is no 
regulatory warning about the dose of atorvastatin in Asians.57
The nocebo response
In patients presenting with only mild myalgia, a nocebo 
response should be considered.58 A nocebo response refers to 
the induction or worsening of symptoms induced by patients’ 
expectations of administered therapies.59 This can affect the 
outcome of a given therapy in a negative way, similar to how 
placebo affects outcome in a positive way.60
In a recent study by Gupta et al, AEs reported with 
atorvastatin therapy during a blinded, randomized, placebo- 
controlled phase were compared with those during an 
unblinded, nonrandomized phase when open-labeled treat-
ment with atorvastatin was continued.61 The study found an 
excess rate of muscle-related AEs when patients and their 
doctors knew that they were on statin therapy in comparison 
to when they were blinded.61 These observations should pro-
vide assurance to both physicians and patients that most AEs 
linked with statins do not actually have a causal relationship.61
Patients who commonly experience these adverse reac-
tions (the nocebo response) either challenge their physician 
about the risks of treatment or simply stop the treatment.58 
Although patients do experience statin-associated side 
effects, the majority of these complaints may represent the 
nocebo response.25 Physicians should evaluate patients’ exist-
ing knowledge or perceptions of statin therapy and try to 
counter the negative perception of exaggerated claims about 
statin-related side effects.33 With the nocebo response being 
so prominent, and yet underrecognized in clinical practice, 
physicians need to be informed on how to detect and handle 
this effect.62
Why is nonadherence to statins 
unique?
Cholesterol-lowering medicines as a class are associated 
primarily with nonadherence.8 Furthermore, adherence 
to medicines for treatment of a symptomless condition, 
such as high lipid levels, is a challenge to both doctor and 
patient.14 It follows that statins may be discontinued at 
rates higher than for other oral medicines used for chronic 
therapy. For example, the more frequent screening of blood 
glucose levels compared with cholesterol levels encourages 
patients to be more adherent to their diabetic medication 
than to statins.14
Patients’ beliefs about medicines or how recent the treat-
ment was initiated were also found to be significant predictors 
of adherence.11 Correspondingly, the nocebo response reflects 
alterations in human psychobiology (brain, body, and behav-
ior) rather than the effect of the medicine.58 For example, 
reporting of SAMS can be a consequence of negative media 
reports about statins or an improper understanding by patients 
of possible statin-associated adverse effects.33
AEs are cited as the most frequent cause of statin discon-
tinuation.14 In a focus group of 18 participants, nonadherence 
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Concerns were raised from information on the Internet, 
uncertainty about the benefits or importance of statins, the 
inconvenience of taking a medicine, and obtaining lipid pro-
file tests on a routine basis.63 In general, unfavorable reports 
found on both social and professional media are a major cause 
for discontinuation of statin therapy. This is because the AEs 
of statins are frequently reported and mostly overstated.8 
The proliferation of absurd and unscientific but seemingly 
persuasive criticism of statins on the Internet has created a 
bad reputation for statins in the public eye.25 Information on 
the Internet can be made available by anyone with little or no 
scientific expertise, and usually promotes statin denial, the 
proposition that cholesterol is not related to heart disease, 
and statin fear, which is the notion that lowering serum cho-
lesterol levels will cause serious AEs, such as muscle or liver 
toxicity.25 A study of 6,74,900 patients revealed that early 
statin discontinuation was associated with negative media 
attention on statins.64
The adherence problem is exacerbated by hesitation 
among doctors to discuss and prescribe statins when there 
are harmful media reports, and compounded by reduced 
patient compliance as a result of increased awareness of 
perceived side effects.65 Failure to correct misleading claims 
about side effects quickly and completely leads patients to 
stop their statin therapy even though they are at high risk of 
cardiovascular events.64,66
Predictors for statin nonadherence
The causes of nonadherence are certainly complex and can be 
broadly classified into three categories: patient related, physi-
cian related, and health care system related (Figure 1). Among 
these, patient-related factors may be the strongest and may be 
further differentiated into voluntary and involuntary factors.14 
Treatment burden (requirement of daily medication), lack of 
symptomatic benefit, large time lag to benefit, and perceived 
or real AEs are perhaps the key causes of nonadherence.





•   Lack of understanding of current
    disease condition
•   Complex medication regimen •   The economics of health care
    systems restricts the time spent
    between the physician and the patient.
    This results in insufficient time to
Provide proper patient education





Offer encouragements and tips to
improve adherence
•   Cost of medication
•   Insufficient clinical monitoring
•   Poor awareness about patient
    adherence
•   Multiple physicians providing varying
    and possibly conflicting details to the
    patients
•   Specialty of prescriber
•   Poor understanding between patient
    and physician
•   Insufficient explanation to patients
    about their medical condition and
    medications (benefits, side effects,
    time needed for medication to work,
    etc)
•   Difficulty accepting disease severity
•   Previous negative experience to
    therapy
•   Skeptical on recommended
    treatment efficacy
•   Poor trust in the health care provider
•   Cultural and ethnic beliefs
•   Low level of health literacy or
    education
•   Increased susceptibility to
    medication adverse effects
•   Other comorbidities or concomitant
    conditions such as “psychological
    problems or cognitive impairments”
•   Unstable family background
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Several factors such as copayment, statin use for either 
primary or secondary prevention, female gender, age, and 
belonging to a minority race are also predictive of nonadher-
ence and statin discontinuation. The number of appointments 
with cardiologists, frequency of LDL tests performed, and 
the simplicity of the medication regimen are linked with 
improved statin adherence.20
A meta-analysis showed that age as a predictor of nonad-
herence follows a U-shaped curve, with the youngest (<50 
years) and oldest (≥70 years) showing lower adherence than 
those in between.14,67,68 Existing comorbidities such as diabetes 
and hypertension are associated with improved adherence.14 
Persistence with statin therapy in older patients declines 
substantially over time, with the greatest drop occurring in 
the first 6 months of treatment.68 Forgetfulness is a common 
reason but there are many factors that can lead up to it, such 
as insufficient prioritization of the importance of medication 
intake or simply disliking the need to swallow a pill.14
Overall, nonadherence is influenced by an interaction 
between various factors, such as patient education, com-
munication between patients and physicians, medication 
regimen, as well as access to health care.69
Measuring adherence
Adherence is defined as the percentage of pills a patient takes 
as prescribed. By convention, a cutoff point of 80% is used to 
categorize adherence to cardiovascular medications into good 
and poor adherence groups.70 Patients are also categorized as 
nonadherent if they discontinue a medication before a certain 
time period. In primary nonadherence, a patient “discontin-
ues” a medication even before filling a prescription once.23
While there is no recognized gold standard method to 
measure adherence, a combination of direct and indirect 
methods can be used to get an accurate measurement of 
adherence in actual practice (Table 2).14
Interventions to improve 
medication-taking behaviors
Generally, about 33% of patients will be adherent to therapy 
just by being given a prescription and asked to take it by 
their physicians, while about 15%–25% will be nonadherent 
despite any intervention.71 Interventions to improve adher-
ence are aimed at the middle 50% of patients who may adhere 
if given support and encouragement.14
Identifying specific barriers for each patient and adopt-
ing suitable techniques to overcome them are necessary to 
improve medication adherence.22 However, individual inter-
ventions, as distinct from a shared responsibility between 
the clinician and patient, tend to be associated with poor 
improvements in adherence. Alternatively, multifaceted 
approaches designed for individual patients are more likely 
to improve long-term adherence to medication.69
A personalized, patient-focused program involving 
frequent interactions with a health care professional or 
a combination of techniques that make use of physician 
communication and pharmacist involvement have shown to 
improve medication adherence and ultimately, better health 
outcomes.72 Figure 2 summarizes various interventions to 
improve medication adherence.
We have not analyzed the cost-effectiveness of individual 
strategies. Comparing costs of different adherence strategies or 
technologies would be a relevant topic for a costs- effectiveness 
analysis, but this is beyond the scope of this review.
Shared decision-making
Current evidence-based clinical guidelines often do not take 
into account specific individual issues. Values, goals, and 
preferences need to be taken into account. Clinical decisions 
should be made based on the concept of “shared decision-
making”.73 Providing positive reassurances that the patient 
is making a good effort to lower risk of a cardiovascular 
Table 2 Measures to quantify medication adherence
Direct methods Indirect methods
•	 Direct observation by health care provider
•	 Measuring blood levels to yield quantitative data 
-	 Costly and time consuming
•	 Patient education/adherence scale
•	 Pill counts
•	 Statistics on repeated prescriptions
•	 Electronic monitoring systems in blister packs
-	 Does not assure if the patient actually ingests the medication or 
whether patient takes the correct dose
•	 Patient diaries
•	 Combined electronic opening, pill counts, and interviews
+		Minimize patient manipulation by revealing openings without pill intake
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event has neither been assessed nor addressed in existing 
guidelines.73 Understanding the patient’s apprehensions about 
therapy is vital to improve adherence. Patient-specific factors 
such as perceptions about their condition, perceived efficacy 
of treatment, and other elements that have been associated 
with nonadherence need to be discussed to avoid poor adher-
ence and adverse treatment outcomes. Health care providers 
need to come up with an educational strategy, tailored to 
each patient’s needs.
The development of shared decision-making tools will 
allow current clinical evidence to be portrayed in simple 
terms such that it allows physicians to help their patients make 
appropriate decisions related to medication use.73
Counseling
Strategies such as hospital staff, other than the physician, 
conducting regular phone counseling on medication adher-
ence, were shown to have an impact on patient survival.74 Data 
strongly suggest medication adherence can be improved as a 
result of this method of weekly communication.13 Predictors 
of nonadherence can also be used to identify those at high 
risk of statin discontinuation for targeted counseling.14 Recent 
international guidelines such as those from the “American 
College of Cardiology/American Heart Association (2013)” 
and the “European Society of Cardiology (2016)” recommend 
that physicians, and allied health care professionals, should 
regularly monitor patients’ adherence to statin therapy.75–77
Patients in whom knowledge and understanding of statins 
and CVD risk factors were improved, adherence to therapy 
was better and the number of people reaching their LDL-C 
goals increased.78 Motivational interviewing techniques can 
help the patient develop a list of treatment goals.8 Likewise, 
physicians can also advocate good practices by encouraging 
patients to set medication reminders, organize medicines in 
pill boxes, and maintain a medicine tracker sheet to help 
improve adherence.
Patient information and education
Enhancing communication between physician and patient 
is crucial to improve patient education and allow patients 
to clarify and resolve any concerns or misconceptions.79 It 
is important for physicians to empower patients to become 
informed medication consumers by educating patients as 
well as family members about their medical condition and 
medicines.8 Educational videos, mobile apps, and audio 
books can help improve knowledge about their conditions.8,80
Suggested topics for patient education can highlight the 
importance of a medicine’s benefit, for example, long-term 
benefits in prevention of CVD with statins. Physicians must 
abandon commonly used fear tactics, as scaring the patient 
Figure 2 Interventions for improving medication adherence.
Notes: Overall, the interventions can be differentiated as “before” and “after” prescription interventions. The strategies are multimodal varying from “patient education/
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will more likely result in decreased adherence.81 Informa-
tion about statins (reasons for prescription, benefits, risks, 
etc.), additional time for discussion with the clinician, and 
written or trustworthy online information about statin risks, 
side effects, and drug interactions, can also help improve 
adherence.14
Education on harmful pseudoscience will also prove 
useful. Products promoted on the Internet commonly imply 
benefits that have no evidence from formal clinical studies 
and could potentially be harmful as well.25 For instance, 
patients are promised that adhering to a certain diet or tak-
ing exotic food supplements can result in a reversal of heart 
disease. These diets are aggressively promoted to patients as 
an alternative to statin medication, promising all the benefits 
without any risk, when in fact there is no scientific basis for 
these claims.
Reminders
Medication reminders by pharmacists, nurses, or therapists 
can improve adherence.13 Techniques commonly involve 
phone calls, SMS texts, mail, and the use of calendar 
reminders. Telephone reminders when used together with 
educational materials were shown to be the most effective 
strategies.16
A Cochrane database review by Schedlbauer et al con-
cluded that “reminding” or “re-enforcement” appeared to be 
the most promising intervention tactic to improve adherence 
to lipid-lowering drugs.8,82 In another study, Derose et al 
investigated statin adherence in 5,216 participants who had 
discontinued statin use within the previous year and found 
that the group that received periodic automated telephone 
calls had a significantly better adherence to statins within 
the year of the study.83
Dose-dispensed medicine
Overall, the use of various types of pill box did not show 
any improvement in adherence by patients when compared 
to usual practices.84 However, this method could be more 
effective when it is used in combination with other forms 
of intervention.84 Multiple studies have reported significant 
improvement in adherence when a drug reminder packaging 
was used with results being much more distinct when it was 
part of a multifaceted approach compared with a single-
faceted approach.85
Dose-dispensed medicines such as the time-specific blis-
ter packs contain the patient’s medication for each time point 
of the day.86 Patient-specific multidose adherence packs also 
contain the medications required for a week and are labeled 
with the day and time of drug administration. Their use 
maintains the ability for individual choice of drug and dose.13
Evidence suggests that the combination of weekly dose-
dispensed blister packs with regular pharmacy counseling on 
adherence demonstrates an absolute increase in adherence 
of one-third when compared with the standard prepacked 
medication in blister cards.13 One study showed that drug 
reminder packaging significantly reduced the mean hospital-
ization rate, a more relevant marker of adherence for patients 
on polypharmacy.85
Reducing pill burden or simplification of 
the drug regimen
A complex medication regimen and high pill burden can also 
lead to nonadherence. Careful reduction in the use of unnec-
essary or unsafe medications, and use of combination and 
once-daily formulations are effective strategies in managing 
polypharmacy and reducing pill burden.87 One such strategy 
is the use of a polypill. Polypills are the combination of 
multiple classes of preventive medications in one pill. Their 
use has demonstrated significant improvement in adherence 
when used instead of usual care in patients with CVD.88 
Less-intensive strategies, such as prescribing products that 
simplify the medication regimen, achieve relatively smaller 
improvements in compliance.89
Digital interventions
Digital interventions that involve the use of modern tech-
nology to develop approaches to improve adherence such 
as smartphone apps are novel solutions.69 By incorporating 
physical physician–patient interactions with technology-
driven medication adherence reminders, electronic medi-
cation reconciliation, and the usage of pharmaceutical 
databases, adherence to medicines may be improved as well.90 
A recent example is the ACC Statin Intolerance App, which 
was developed to guide physicians how to manage and treat 
patients who experience muscle symptoms while on statin 
therapy. Physicians would be able to determine if a patient is 
really intolerant to their statin medication, follow guidelines 
in managing and treating muscle symptoms while on statins, 
and compare between different statin characteristics or any 
potential drug interactions.91
Upcoming potential digital interventions also include 
technotherapeutics. Technologies are gradually expanding in 
the health care arena to capture previously unavailable data 
and to generate new knowledge about patients.92 The use of 
new technological devices even allows for previously unavail-
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via a tiny microchip inserted into the body. This information 
can then be transmitted to health care professionals.92 They 
have the potential to track physiological responses and treat-
ment adherence with exact precision. A prompt signal will 
be transmitted when there is nonadherence to a medication 
regimen.92 This new technological device may be able to 
improve the therapeutic management of chronic conditions, 
maximize clinical outcomes, facilitate communication with 
health care providers, and individualize patient care.92 Tech-
notherapeutics is, however, expensive and complex. Also, 
its design has limitations as it places the responsibility of 
adherence primarily on the patient.
Importance of combined pharmacist and/
or nurse participation
Pharmacists are uniquely positioned to interact more frequently 
with patients than other health care providers. Pharmacists are 
better able to emphasize proper medication-taking behaviors 
and address issues about the patient’s medication adherence 
by using their access to medication refill  information.93 By 
enlisting ancillary health care providers such as pharmacists, 
additional motivation to patients can be provided.
Some techniques include phone calls, counseling, medi-
cation review, home visits, and comprehensive pharmacy 
care focusing on patient education and the importance of 
 adherence. Another technique can involve the implementation 
of a reward system by providing positive feedback whenever 
a treatment goal is attained according to the treatment plan.8 
Ultimately, this could even include reduced payments for 
health insurance schemes.
Based on multiple studies, integration of pharmacist and/
or specialized nurse practitioner counseling with a focus on 
adherence demonstrated the most noteworthy improvements 
in medication habits.16 The use of specialized nurse practitio-
ners for follow-up has even led to a reduction in LDL-C of 
about 0.9 mmol/L from baseline.86 Integration of a pharmacy/
nurse program is likely to achieve substantial improvements 
in medication adherence and significant LDL-C reductions.
Conclusion
Nonadherence to statins is exceptionally common and has been 
undervalued by the majority health care professionals as well 
as professional organizations responsible for formulating lipid 
management guidelines. Identifying at-risk patients and initiat-
ing treatment remains a priority, but if medication adherence is 
ignored, this will result in wasted efforts, resources and lives. 
We have to intensify our efforts to overcome this formidable 
barrier if our goal is to preserve our patients’ health. We need to 
empower our patients so they can recognize sham information 
found on the Internet that promote alternative remedies, created 
by people with little or no scientific expertise. The only way 
to address this challenge is allocating time to talk and interact 
with patients. This can be done by physicians or dedicated 
hospital staff on an individual basis or in groups. Support 
from health authorities for educating the public and enlisting 
media support should complement individualized strategies.
Specific guidelines to improve adherence are urgently 
needed. Evidence-based interventions to improve adherence are 
available and should be effectively integrated in patient man-
agement. Various health care providers including physicians, 
pharmacists, and nurses need to collaborate and communicate 
with patients to address concerns and discuss the risks and 
benefits of long-term statin therapy. Identification of relevant 
approaches and techniques by health care providers can improve 
adherence, but most importantly, physician and patient need 
to create a trusting alliance; this will promote statin adherence 
and ultimately reduce morbidity and increase life expectancy.
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